Indication
Antithrombin III deficiency
Antithrombin III deficiency is a rare thrombophilic disorder of the hematologic and vascular systems characterized by inadequate levels or impaired function of antithrombin, a key natural anticoagulant glycoprotein. Read more about Antithrombin III deficiency
2 drugs 2 manufacturers
Drugs that treat it
Common Antithrombin III deficiency therapies.
ATRYN (antithrombin III, human recombinant)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAntithrombin III deficiency is a rare thrombophilic disorder of the hematologic and vascular systems characterized by inadequate levels or impaired function of antithrombin, a key natural anticoagulant glycoprotein.
The condition can be hereditary, stemming from pathogenic variants in the *SERPINC1* gene, or acquired secondary to decreased hepatic synthesis, excessive renal protein loss, consumptive coagulopathies, or critical illness.
Pathophysiologically, the loss of antithrombin-mediated neutralization of thrombin, factor Xa, and related serine proteases creates an uninhibited procoagulant state.
Consequently, affected individuals have a markedly heightened susceptibility to recurrent venous thromboembolism, most commonly presenting as deep vein thrombosis and pulmonary embolism.
- nih.gov
Antithrombin III deficiency is a rare thrombophilic disorder of the hematologic and vascular systems characterized by inadequate levels or impaired function of antithrombin, a key natural anticoagulant glycoprotein The condition can be hereditary, stemming from pathogenic variants in the *SERPINC1* gene, or acquired secondary to decreased hepatic synthesis, excessive renal protein loss, consumptive coagulopathies, or critical illness Pathophysiologically, the loss of antithrombin-mediated neutra...
- nih.gov
Antithrombin III deficiency is a rare thrombophilic disorder of the hematologic and vascular systems characterized by inadequate levels or impaired function of antithrombin, a key natural anticoagulant glycoprotein Consequently, affected individuals have a markedly heightened susceptibility to recurrent venous thromboembolism, most commonly presenting as deep vein thrombosis and pulmonary embolism
- nih.gov
The condition can be hereditary, stemming from pathogenic variants in the *SERPINC1* gene, or acquired secondary to decreased hepatic synthesis, excessive renal protein loss, consumptive coagulopathies, or critical illness
- clevelandclinic.org
Consequently, affected individuals have a markedly heightened susceptibility to recurrent venous thromboembolism, most commonly presenting as deep vein thrombosis and pulmonary embolism
Personalize your experience
Follow Antithrombin III deficiency and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.